- Home
- UWMC vs ANAB Comparison
UWMC vs ANAB Comparison
Compare UWMC & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UWMC
- ANAB
- Stock Information
- Founded
- UWMC 1986
- ANAB 2005
- Country
- UWMC United States
- ANAB United States
- Employees
- UWMC N/A
- ANAB N/A
- Industry
- UWMC Finance: Consumer Services
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- UWMC Finance
- ANAB Health Care
- Exchange
- UWMC Nasdaq
- ANAB Nasdaq
- Market Cap
- UWMC 872.1M
- ANAB 759.5M
- IPO Year
- UWMC N/A
- ANAB 2017
- Fundamental
- Price
- UWMC $4.31
- ANAB $22.23
- Analyst Decision
- UWMC Hold
- ANAB Buy
- Analyst Count
- UWMC 8
- ANAB 10
- Target Price
- UWMC $6.86
- ANAB $42.25
- AVG Volume (30 Days)
- UWMC 5.6M
- ANAB 559.5K
- Earning Date
- UWMC 05-06-2025
- ANAB 05-05-2025
- Dividend Yield
- UWMC 9.30%
- ANAB N/A
- EPS Growth
- UWMC N/A
- ANAB N/A
- EPS
- UWMC N/A
- ANAB N/A
- Revenue
- UWMC $2,486,541,000.00
- ANAB $111,872,000.00
- Revenue This Year
- UWMC $7.37
- ANAB N/A
- Revenue Next Year
- UWMC $22.42
- ANAB $9.72
- P/E Ratio
- UWMC N/A
- ANAB N/A
- Revenue Growth
- UWMC 10.39
- ANAB 387.20
- 52 Week Low
- UWMC $3.89
- ANAB $12.21
- 52 Week High
- UWMC $9.74
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- UWMC 47.87
- ANAB 62.32
- Support Level
- UWMC $3.89
- ANAB $20.50
- Resistance Level
- UWMC $4.25
- ANAB $22.84
- Average True Range (ATR)
- UWMC 0.18
- ANAB 1.28
- MACD
- UWMC 0.05
- ANAB 0.12
- Stochastic Oscillator
- UWMC 84.16
- ANAB 83.24
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).